Prinssen, Eric

Maternal immune activation and abnormal brain development across CNS disorders

Knuesel, I., Chicha, L., Britschgi, M., Schobel, S. A., Bodmer, M., Hellings, J. A., Toovey, S., & Prinssen, E. P. (2014) · Nature Reviews Neurology

Tryptophan and brain disordersNeuroinflammation and Neurodegeneration Mechanisms

Cited by 880

Fenobam: A Clinically Validated Nonbenzodiazepine Anxiolytic Is a Potent, Selective, and Noncompetitive mGlu5 Receptor Antagonist with Inverse Agonist Activity

Porter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 308

A combined marble burying–locomotor activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants

Nicolas, L. B., Kolb, Y., & Prinssen, E. P. M. (2006) · European Journal of Pharmacology

Neurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

Cited by 234

CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor

Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics

Neuroscience and Neuropharmacology ResearchReceptor Mechanisms and Signaling

Cited by 118

Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression

Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 107

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets

Bespalov, A., Steckler, T., Altevogt, B., Koustova, E., Skolnick, P., Deaver, D., Millan, M. J., Bastlund, J. F., Doller, D., Witkin, J., et al. (2016) · Nature Reviews Drug Discovery

Animal testing and alternativesComputational Drug Discovery Methods

Cited by 84

Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases

Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., et al. (2015) · Journal of Medicinal Chemistry

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 66

The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys

Podlesnik, C. A., Ko, M.-C., Winger, G., Wichmann, J., Prinssen, E. P., & Woods, J. H. (2011) · Psychopharmacology

Neuropeptides and Animal PhysiologyPain Mechanisms and Treatments

Cited by 40